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Abstract: BACKGROUND: Patients with pulmonary arterial hypertension (PAH) and distal chronic
thromboembolic pulmonary hypertension (CTEPH) who still reveal risk factors of worse prognosis on
double combination therapy may benefit from add-on therapy with the novel oral selective prostacy-
clin receptor agonist selexipag. METHODS: We reviewed all patients with PAH/distal CTEPH in the
Zurich cohort who received selexipag as add-on to oral combination therapy and retrieved New York
Heart Association (NYHA) functional class, 6-min walk distance (6MWD), NT-pro-BNP, quality of life
questionnaires (CAMPHOR and EuroQoL), tricuspid pressure gradient (TPG) by echocardiography and
cardiopulmonary exercise test parameters (power output and oxygen uptake). RESULTS: Twenty-three
patients with PAH/CTEPH (20/3), 14 females, median (quartiles) age 56 (46; 66) years received an
oral triple therapy containing selexipag at a median dose of 2000 (1600; 3100) mcg during 221 (113;
359) days. The following parameters were stabilized from baseline to last FU: 6MWD (440 (420; 490)
to 464 (420; 526) m), NYHA class (three to two), NT-pro-BNP (326 (167; 1725) to 568 (135; 1856)
ng/l), TPG, power output, and oxygen uptake. Quality of life reflected by the CAMPHOR and EuroQoL
improved. CONCLUSIONS: Early initiation of triple oral combination therapy including selexipag in
PAH/CTEPH with intermediate risk factor profile may help to stabilize functional class, exercise per-
formance, and pulmonary hemodynamics in a real-life setting and potentially improves quality of life.
Whether these beneficial effects can be truly attributed to the addition of selexipag should be addressed
in future randomized controlled trials.
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Purpose:  Patients with pulmonary arterial hypertension (PAH) and distal chronic 
thromboembolic pulmonary hypertension (CTEPH) who still reveal risk factors of worse 
prognosis on double combination therapy may benefit from add-on therapy with the novel 
oral selective prostacyclin-receptor agonist selexipag.    
Methods: We reviewed all patients with PAH/distal CTEPH in the Zurich cohort who received 
selexipag as add-on to oral combination therapy and retrieved New York Heart Association 
(NYHA) functional class, 6 minute walk distance (6MWD), NT-pro-BNP, quality of life 
questionnaires (CAMPHOR and EuroQoL), tricuspid pressure gradient (TPG) by 
echocardiography and cardiopulmonary exercise test parameters (power output and oxygen 
uptake).  
Results: 23 patients with PAH/CTEPH (20/3), 14 females, median (quartiles) age 56 (46;66) 
years received an oral triple therapy containing selexipag at a median dose of 2000 
(1600;3100) mcg during 221 (113;359) days. The following parameters stabilized from 
baseline to last FU: 6MWD (440 (420;490) to 464 (420;526) meters), NYHA class (3 to 2), 
NT-pro-BNP (326 (167;1725) to 568 (135;1856) ng/l), TPG, power-output and oxygen 
uptake. Quality of life reflected by the CAMPHOR and EuroQoL improved.  
Conclusions: Early initiation of triple oral combination therapy including selexipag in 
PAH/CTEPH with intermediate risk factor profile may contribute to stabilize functional class, 
exercise performance and pulmonary hemodynamics in a real life setting and potentially 
improves quality of life. Whether these beneficial effects can be truly attributed to the addition 







































































Precapillary pulmonary hypertension (PH) is a serious condition leading to impaired exercise 
tolerance, quality of life and reduced life expectancy if untreated (1). In the absence of 
relevant lung or heart disease, the two major forms are pulmonary arterial and chronic 
thromboembolic pulmonary hypertension (PAH and CTEPH). Whereas symptoms in many 
patients with CTEPH can substantially improve with pulmonary endarterectomy or balloon-
pulmonary angioplasty, different medical therapies ameliorate symptoms, exercise capacity 
and quality of life in PAH and in persisting CTEPH after treatment or inoperable CTEPH, 
which share pathogenic features with PAH (1-5). PH is characterized by the vasoconstriction 
of pulmonary artery smooth muscles, vascular remodeling and endothelial cell proliferation 
(6). Three major involved pathogenic pathways are therapeutically addressed to date: the 
nitric oxide, endothelin and prostacyclin pathways.  
Oral drugs targeting the endothelin and nitric oxide pathways are commonly initiated in 
ambulatory patients, whereas initial intravenous prostanoid are used in patients presenting 
with advanced disease stages in right heart failure (1). Recent randomized controlled trials 
like the AMBITION (7), PATENT PLUS (8) and SERAPHIN trial (9) have shown that initial 
early combination therapy addressing both the endothelin- and nitric oxide pathways have 
higher efficacy in improving symptoms, clinical worsening and exercise capacity in PAH, and 
thus current recommendations support the early use of combination therapy, which is 
widespread initiated as initial oral combination therapy (1, 7, 9-12). Initial use of triple 
combination therapy addressing all available pathways was mainly reserved for severe cases 
in NYHA functional class IV due to the need of an indwelling catheter for continuous 
prostanoid therapy. Selexipag is an oral highly selective prostacyclin receptor agonist and 
has been approved by the FDA in December 2015 allowing an oral combination therapy 
targeting the prostacyclin pathway. In a placebo-controlled phase 2 study with PAH-patients 
receiving single or double therapy, addition of selexipag significantly reduced the pulmonary 
vascular resistance (PVR) by 30.3% after 17 weeks of treatment (13). In a large randomized 
placebo-controlled phase 3 study (GRIPHON) including PAH patients on oral mono or dual 
therapy for PAH, selexipag reduced the primary composite end point of death or a 
complication related to PAH by 40% (hazard ratio in the selexipag group as compared with 
the placebo group 0.6, p<0.001))(14). This treatment effect was driven by differences in 
disease progression and hospitalization as there was no significant difference in mortality 
between the two study groups as disease progression was a predefined endpoint and 
terminated the study for the patient in investigation (14). Subgroup analysis in PAH 
associated with connective tissue disease (CTD) revealed similar improvements of the same 
primary composite endpoint (15). The role of combination therapy in distal inoperable or 




































































CTEPH is medically treated in analogy to PAH as both share similar pathogenic features (5, 
10, 16, 17).   
Early combination therapy is commonly used in clinical practice (10, 16) and since the 
availability of selexipag in Switzerland, triple oral combination therapy including selexipag is 
commonly offered to patients not fulfilling all criteria of favorable prognosis. There are 
currently very scarcely data available on the clinical course of patients with PAH or CTEPH 
receiving selexipag in real life conditions. We therefore analyzed all patients in the Zurich PH 
cohort who received triple therapy with selexipag.  
 
Methods 
This retrospective cohort study complied with the ethical laws in Switzerland and all patients 
have signed informed consent for the Zurich PH cohort study (KEK 2014-0214).  
Study design and patients 
This is a retrospective analysis of data from all adults (>18y) with PAH or distal CTEPH in 
whom selexipag was initiated at the University Hospital Zurich between July 2016 and April 
2018 due to not fulfilling all criteria for favorable prognosis according to the latest guidelines 
(1). The data from the last visit before starting selexipag were considered as baseline. Right 
heart catheterization (RHC) data of the last RHC available before the start of selexipag was 
retrieved. Variables assessed at baseline, at 2-4 months follow-up (FU) and at the last visit or 
at the last visit before stopping selexipag included the NYHA class, the six minute walk 
distance (6MWD), the N-terminal pro brain natriuretic peptide (NT-proBNP), 
echocardiographic assessments of the tricuspid pressure gradient (TPG), as surrogate for 
pulmonary artery pressure, the tricuspid annual plane systolic excursion (TAPSE) and the 
systolic/diastolic fractional area change of the right ventricle (FAC%) as markers of cardiac 
function (18), and also the maximal power output, oxygen uptake and VE/VCO2 slope 
retrieved from maximal ramp cycle cardiopulmonary exercise test (CPET). Quality of life 
questionnaires (Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), 
EuroQoL and Minnesota living with heart failure questionnaire (MLHF)) as well as patient 
self-reported therapeutic effect (I feel better, worse, equal) and self-reported health status 
(scaled from very bad, bad, not so good, good, very good and excellent) were retrieved at 
baseline and after on average 6 months of FU. We compared and statistically analyzed the 
variables between baseline and FU as well as between baseline and ‘last visit’. The ‘last visit’ 
consisted in the last available visit or the last visit before stopping selexipag. In patients who 




































































stratification strategy of the last guidelines (1) to categorize patients as low, intermediate or 
high risk at baseline, following the validation strategy of Kylhammar et al (19). 
Treatment regimen 
All patients received an oral double therapy with endothelin receptor antagonist (ERA) and 
phosphodiesterase type 5 (PDE-5) inhibitors or soluble guanylate cyclase (sGC) stimulator. 
One patient on inhaled Iloprost was switched to selexipag and  one patient was pretreated 
also with imatinib since years. Selexipag treatment was initiated at a dose of 200 mcg bid 
and increased weekly in increments of 200 mcg bid until the maximal dose of 1600 mcg bid 
was reached or until unmanageable adverse effects developed (headache, jaw pain, nausea 
or diarrhea). Specialized nurses controlled the up-titration with weekly telephone calls 
according to clinical practice.  
Statistical analysis 
Data were stored in the secure database of the Zurich PH cohort. Analysis was performed 
using the SPSS Statistics 25. All data are expressed as median (quartiles). Comparison of 
NYHA class, 6MWD, blood-, echocardiography- and CPET- parameters were performed 
using non-parametric Wilcoxon test due to non-normal distribution of the majority of data. A 
p-value < 0.05 was considered statistically significant. We calculated the Cohen’s effect size 
for quality of life parameters as the mean change during follow-up divided by the standard 
deviation at baseline for the quality of life questionnaires items. Due to the exploratory nature 
of our clinical study, we did not perform an a priori sample size calculation. However, we 
computed nonparametric 95% confidence intervals of changes in quality of life to assess the 
precision of these outcomes. 
 
Results 
Baseline patient characteristics 
Baseline characteristics and therapy of 23 patients (14 females, median age 56 years) who 
had selexipag added to oral combination therapy are shown in table 1 and table 2. There 
were only 3 patients with distal CTEPH in this observational study, two of them with 
persisting PH after pulmonary endarterectomy and one patient was inoperable. Functional 
class, 6MWD and echocardiography were available for all patients at baseline, CPET in 12. 
CPET at baseline showed a reduced maximal oxygen uptake (peak VO2max), a reduced 
power output and increased VE/VCO2 slope. According to the risk classification proposed by 
Boucly et al (1, 20), 7 patients were in the low risk, 15 in the intermediate risk and 1 patient in 




































































Follow-up at 2-4 months 
Follow-up data at visit 2-4 months after start of selexipag was available in 20 patients (table 2 
and figure 1), the daily selexipag dose achieved was 2200 (1600; 3200) mcg. The 6MWD 
improved significantly to 447 (420; 507) meters (+7m, p 0.035). The resting peripheral 
oxygen saturation (SpO2) and the Borg scale at peak 6MWD improved significantly (SpO2 
from 96% (92;97) to 97% (94;98), p 0.043, Borg from 5 (4;7) to 4 (3;5) points, p 0.009). The 
NYHA class and NT-pro-BNP remained stable. Individually analyzed, 12 patients remained in 
the same NYHA class, 5 patients improved, and 3 deteriorated. Follow-up echocardiographic 
and CPET-variables from 8 respectively 5 patients showed no difference compared to 
baseline.  
Last visit 
Data for the last visit was available from 22 patients, after 221 (113; 359) days of observation 
(table 2 and figure 1). The 6MWD remained stable with 464 (420; 526) meters in comparison 
with the baseline 6MWD. The SpO2 at rest and at peak exercise, the Borg scale and the NT-
pro-BNP remained stable. Even though the median pro-BNP doubled at the last visit in 
comparison with the baseline, this increase was not significant. Overall, there was no 
difference in the NYHA class from baseline to the last visit (median 3 vs. 2, p 0.14). 
Individually analyzed, 13 patients remained in the same NYHA class, 7 patients improved 
and 2 deteriorated (figure 2). The echocardiographic (n=18) and the CPET (n=13) variables 
remained stable. The daily selexipag dose achieved was 2000 (1600; 3100) mcg. 
Quality of life 
Quality of life questionnaires were available in half of the patients (table 3). There was a 
significant improvement in the symptoms and quality of life items of the CAMPHOR 
questionnaire, whereas the activity item remained stable. The effect size of the change of  
the CAMPHOR was between 0.4 to 0.8 .There was also a significant improvement in the 
EuroQoL visual analogue scale from 55 to 65 (a higher score meaning a better quality of life), 
with a good effect size of 0.8. More patients rated themselves as better under additional 
selexipag therapy as showed in the patient self-reported therapeutic effect questionnaire and 
the self-reported health status stayed stable (a lower score indicating a better status), with a 
good effect size of 1.2 and 0.5 respectively . The MLHF questionnaire was low at baseline 
and remained stable under therapy (a lower score indicating a better quality of life). 
Stop of selexipag 
Six patients stopped selexipag during the observational period. Two patients (1 PAH, 1 




































































insufficient clinical stabilization and listing for lung transplantation. One patient with 
congenital heart disease stopped selexipag because of intense head- and muscle ache and 
worsening of SpO2. One PAH-patient stopped selexipag due to persistent diarrhea and 
pruritus and two because of lack of subjective benefit. The therapy duration for the patients 
who stopped selexipag was 218 (111; 254) days and the selexipag dose 2400 (1000; 3000) 
mcg.  
Mortality and hospitalization 
One 73 years old patient died during the observational period due to a septic shock with 
staphylococcus aureus 283 days after the initiation of selexipag therapy. This death was not 
related to PAH and its therapy. One patient was hospitalized due to an influenza infection 
and one due to progressive right heart failure necessitating intravenous diuretic therapy.  
 
Discussion 
Our retrospective study describes for the first time the clinical outcome of patients with PAH 
or distal CTEPH treated with selexipag as add-on to oral combination therapy in a real-life 
setting. We found that triple oral combination therapy adding selexipag was generally well 
tolerated and may contributed to stabilize exercise capacity, NYHA class, NT-pro-BNP, 
pulmonary artery pressure and right heart function and available questionnaire assessment 
revealed improved quality of life scores and symptoms.  
Initial combination therapy has been shown efficacy in randomized trials and delayed 
disease progression and its early initiation even in patients with more favorable risk factor 
profiles may be beneficial (1). According to recently published risk assessments strategies, 7, 
15 and 1 patients of the present collective would be assigned to low, intermediate and high 
risk (19-21). But even in the low risk group, the patients did not fulfil all beneficial criteria, 
which is why we proposed escalation of drug therapy. 
The post-hoc analysis of the GRIPHON study (22) analyzed the subgroup of patients (n=376) 
who received double oral therapy with ERAs and PDE-5 inhibitors before adding selexipag 
versus placebo. In this subgroup, selexipag reduced the composite end-point of death or a 
complication related to PAH by 37% compared to placebo, indicating a similar effect as in the 
overall GRIPHON population (14).    
The 6MWD is one of the most widespread used prognostic marker and study endpoint, 
however, the observed changes are usually less in combination therapy trials (23). In our 
retrospective real life cohort after a median treatment time of 8 months, the median 6MWD 




































































significant but relates to the treatment effect of 12 meters in GRIPHON (12). Exercise 
capacity assessed by CPET was also stabilized, reflected by a trend towards an improved 
peakVO2, VE/VCO2 slope and power output. Improving CPET would be of high relevance for 
patients, as CPET parameters have a prognostic value predicting survival and time to clinical 
worsening (24).  NYHA class remained stable in the majority of patients (13 patients), 
improved in 7 and deteriorated in 2 patients. Thus, the percentage of patients not revealing a 
worsening of the NYHA class in our cohort is slightly higher than in GRIPHON (91 vs. 78%) 
and reassuring in a real-life setting. Echocardiographic assessment at the last visit showed 
that all assessed parameters remained stable on oral triple combination therapy and so did 
the NT-pro-BNP.   
An improved quality of life is an important and patient-relevant outcome parameter, and the 
measurement of the quality of life endpoint enables to have a more comprehensive and 
relevant assessment of therapeutic effects. A better quality of life was furthermore predictive 
of the prognosis in PAH/CTEPH (4). The CAMPHOR was designed as a disease-specific 
score to assess symptoms, activity limitations and quality of life. It has a good internal 
consistency and reproducibility and its German version has also been validated (25, 26). The 
significant improvement in the symptoms and quality of life items of the CAMPHOR 
questionnaire with an effect size ranging from 0.4 to 0.8 depending on the items, which is 
concordant with the described ranges of the effect size in the literature and is clinically 
relevant (27).  It is thus patient relevant and underscores the potential use of early initiated 
triple combination therapy. The fact that the item activity of the CAMPHOR questionnaire 
remained stable again points towards a stabilization on therapy and underscores the fact that 
further improvement in exercise capacity/activity might be difficult to achieve in pretreated 
patients. There was also a significant improvement in the EuroQoL visual analogue scale 
(similar to a thermometer), which is a standardized non-disease specific instrument for 
assessing quality of life (28). The MLHF questionnaire has been shown to be a significant 
predictor of outcome in a prospective study investigating the performance and clinical 
relevance of the MLHF in PAH and CTEPH patients (4). The patient self-reported therapeutic 
effect and health status showed also an amelioration and stabilization, here also with a high 
effect size of ≥ 0.5.To our knowledge, this is the first report on quality of life measures on 
selexipag, showing an amelioration in two important disease-specific scores and parameters 
of global assessments.  
Our study has several limitations. The major one is that this is a retrospective analysis in a 
relatively small number of patients, particularly the CTEPH group was very small and thus 
will not allow subgroup analysis concerning CTEPH alone.  As we have no control group 
available, it remains speculative whether stabilization in this cohort was due to the addition of 




































































Although all patients had some factor of unfavorable prognosis, the majority was in an 
intermediate-to low risk profile. The fact that two patients were switched to an intravenous 
prostanoid during the course of the analysis underscores the importance of close follow-up of 
this patients in a tertiary care center.   
In conclusion, oral triple combination therapy by adding selexipag to an established double 
combination therapy may contributed to stabilization of the NYHA class, exercise capacity 
and hemodynamics, and improves quality of life in patients with PAH or distal CTEPH with 
risk parameters for unfavorable prognosis. Further randomized trials should assess the value 
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23 patients with a baseline visit and start of selexipag 
7 stop selexipag 
 2 change to i.v. prostacyclin 
 2 side effects 
 2 lack of subjective benefit 
 1 death 
22 patients last visit or last visit before stopping selexipag  
15 patients with ongoing oral 
triple combination therapy 
20 patients had a follow-up visit 2-4 
months after start selexipag 
Figure 1 Click here to access/download;Figure;Figure1-Flow-
chart_UL.docx
Figure 2 Click here to access/download;Figure;Figure2-last-version.jpg
Table 1: Patient’s baseline characteristics 
Subjects 23 
Age years  56 (46; 66) 
Time from diagnosis to start of selexipag (months) 24 (6; 70)  
Female  14 (61%) 
Body mass index (kg/m2) 25.6 (23; 29) 
PH classification 
PAH WHO group 1 
Idiopathic 
Associated with congenital heart disease 
Associated with connective tissue disease 























Baseline hemodynamics right heart catheter n=22 
Mean pulmonary artery pressure (mmHg) 
Right atrium pressure (mmHg) 
Pulmonary capillary wedge pressure (mmHg) 
Pulmonary vascular resistance (WU) 
Cardiac output (l/min) 
Cardiac index (l/min/m2) 
 
48 (42; 54)  
8.5 (5; 13) 
11 (9; 12) 
8 (6; 10) 
4.8 (4; 5.8) 
2.8 (2.4; 3.3) 
PAH targeted therapy 
Endothelin receptor antagonist  
Phosphodiesterase 5 inhibitor 
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Values are expressed as median (quartiles) or number (%). 
PH: pulmonary hypertension, PAH: pulmonary arterial hypertension, CTEPH: chronic thromboembolic pulmonary hypertension, 









Table 2: Baseline data and outcomes at follow-up 2-4 months and at the last visit 
 
   
Baseline 
  
Follow-up 2-4 months 




































6 minute walk test n=23  n=19  n=19  
Distance (m)  440 (420; 490)  447 (420; 507)  *   464 (420; 526) 
SpO2 resting (%)  96 (92; 97)  97 (94; 98)  *  95 (92; 97) 
SpO2 peak exercise (%)  88 (79; 94)  90 (84; 92)  83 (76; 93) 
Heart rate peak exercise (bpm)  128 (114; 137)  121 (110; 135)  116 (104; 134) 
Blood pressure peak exercise 
(mmHg) 
systolic, diastolic 
 140 (121; 169) 
74 (71; 95) 
 126 (116; 145) 
73 (66; 81) 
 137 (114; 148) 
75 (68; 79) 
Borg scale  5 (4; 7)  4 (3; 5)  *  4 (4; 6) 
Blood parameter n=22  n=20  n=22  
NT-pro-BNP (ng/l)  326 (167;1725)  243 (130; 892)  568 (135, 1856) 
Cycle cardiopulmonary 
exercise test 
n=12  n=5  n=13  
Peak VO2 (ml/kg/min)  12 (10; 15)  17 (14; 20)  16 (12; 17) 
VE/VCO2 Slope  40 (33 ; 49)  30 (29; 34)  37 (30; 43) 
Power output (watt)  71 (62; 91)  69 (66; 105)  94 (66; 105) 
Echocardiography 
 
n=23  n=8  n=18  
Tricuspid pressure gradient 
(mmHg) 
 54 (46;72)  50 (38; 57)  48 (37; 66) 
Tricuspid annual plane systolic 
excursion (mm) 
 17 (13;21)  13 (12; 17)  16 (13; 20) 
Right ventricular systolic/diastolic 
fractional area change (%) 
 29 (25; 36)  31 (28; 37)  29 (21; 36) 
Left ventricular ejection fraction 
(%) 
 61 (59; 65)  62 (60; 64)  61 (56; 65) 
Selexipag dose per day 
(mcg) 
   2200 (1600; 3200)  2000 (1600; 3100) 
Therapy duration (days)    89 (59; 116)  221 (113; 359) 
 
Values are expressed as median (quartiles). p<0.05 was considered as statistically significant change from baseline and is marked 
with *. SpO2: peripheral oxygen saturation, NT-pro-BNP: N-terminal brain natriuretic peptide, peak VO2: maximal oxygen uptake. 








Table 3: Quality of life at baseline and during therapy with selexipag  
 
 
Values are expressed as median (quartiles). CI: 95% confidence interval. P-values by Wilcoxon matched pair test from baseline to 
follow-up are shown. CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review. CAMPHOR, self-reported therapeutic 
effect, self-reported health status and Minnesota living with heart failure questionnaire: a lower score indicates a better status. 
EuroQoL: a higher score indicates a better quality of life. Effect size is calculated as mean change during follow-up divided 
by the pooled standard deviation (Cohen’s d).  
 n Baseline n Follow-up p-value Effect size (CI) 
CAMPHOR 14  13    
  symptoms  8 (5;11)  4 (3;8)  0.014 -0.68 (-1.26 to -0.11) 
  activity  9 (6;10)  7 (5;9) 0.303 -0.36 (-1.07 to 0.35) 
  quality of life  3 (1;5)  1 (0;2) 0.041 -0.42 (-0.80 to -0.03) 
EuroQoL visual analog scale 14 55 (43;64) 12 65 (60;72)  0.039 0.65 (0.09 to 1.21) 
Self reported therapeutic effect 11 2 (2;3) 11 1 (1;2)  0.046 -1.26 (-2.38 to -0.13) 
Self reported health status  11 4 (3;4) 11 3 (3;4) 0.317 -0.49 (-1.65 to 0.67) 
Minnesota living with heart 
failure questionnaire 
14  11    
  general score  22 (9;43)  23 (17;31) 0.45 -0.27 (-0.86 to 0.32) 
  physical  12 (7;20)  11 (9;15) 0.44 -0.34 (-0.95 to 0.26) 
  emotional  4 (1;11)  3 (2;7) 0.26 -0.36 (-1.01 to 0.29) 
Table 1: Patient’s baseline characteristics 
Subjects 23 
Age years  56 (46; 66) 
Time from diagnosis to start of selexipag (months) 24 (6; 70)  
Female  14 (61%) 
Body mass index (kg/m2) 25.6 (23; 29) 
PH classification 
PAH WHO group 1 
Idiopathic 
Associated with congenital heart disease 
Associated with connective tissue disease 























Baseline hemodynamics right heart catheter n=22 
Mean pulmonary artery pressure (mmHg) 
Right atrium pressure (mmHg) 
Pulmonary capillary wedge pressure (mmHg) 
Pulmonary vascular resistance (WU) 
Cardiac output (l/min) 
Cardiac index (l/min/m2) 
 
48 (42; 54)  
8.5 (5; 13) 
11 (9; 12) 
8 (6; 10) 
4.8 (4; 5.8) 
2.8 (2.4; 3.3) 
PAH targeted therapy 
Endothelin receptor antagonist  
Phosphodiesterase 5 inhibitor 
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Values are expressed as median (quartiles) or number (%). 
PH: pulmonary hypertension, PAH: pulmonary arterial hypertension, CTEPH: chronic thromboembolic pulmonary hypertension, 
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